Isoniazid therapy in Parkinson's disease
Identifieur interne : 006543 ( Main/Exploration ); précédent : 006542; suivant : 006544Isoniazid therapy in Parkinson's disease
Auteurs : O. S. Gershanik [Argentine] ; M. R. Luquin [Espagne] ; O. Scipioni [Argentine] ; Obeso [Espagne]Source :
- Movement Disorders [ 0885-3185 ] ; 1988.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Antiparkinson agent, Chemotherapy, Dyskinesia, Drug-Induced (cerebrospinal fluid), Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Dyskinesias, Female, Human, Humans, Isoniazid (cerebrospinal fluid), Isoniazid (pharmacokinetics), Isoniazid (therapeutic use), Levodopa (adverse effects), Male, Middle Aged, Nervous system diseases, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Treatment.
- MESH :
- chemical , adverse effects : Levodopa.
- chemical , cerebrospinal fluid : Isoniazid.
- cerebrospinal fluid : Dyskinesia, Drug-Induced.
- complications : Parkinson Disease.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- chemical , pharmacokinetics : Isoniazid.
- chemical , therapeutic use : Isoniazid.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
The effect of isoniazid on levodopa‐induced dyskinesias has been evaluated in 20 patients with Parkinson's disease, following a serendipitous observation that choreic dyskinesias induced by levodopa in one parkinsonian patient were markedly reduced during treatment with isoniazid for tuberculous infection. A mean average isoniazid dose of 290 mg was given without any change in current antiparkinsonian treatment. “Benefit of dose” choreic dyskinesias were markedly reduced in 18 patients within the first few weeks of treatment. This effect was accompanied by an intolerable worsening of parkinsonian signs. All patients returned to their basal situation after isoniazid interferes with the therapeutic action of levodopa and dopamine agonists. The precise mechanism by which this action occurred is not known, but several possible explanations are discussed.
Url:
DOI: 10.1002/mds.870030205
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003199
- to stream Istex, to step Curation: 003199
- to stream Istex, to step Checkpoint: 004543
- to stream PubMed, to step Corpus: 005013
- to stream PubMed, to step Curation: 005013
- to stream PubMed, to step Checkpoint: 005032
- to stream Ncbi, to step Merge: 004618
- to stream Ncbi, to step Curation: 004618
- to stream Ncbi, to step Checkpoint: 004618
- to stream Main, to step Merge: 009912
- to stream PascalFrancis, to step Corpus: 003A57
- to stream PascalFrancis, to step Curation: 002D68
- to stream PascalFrancis, to step Checkpoint: 003A45
- to stream Main, to step Merge: 009959
- to stream Main, to step Curation: 006543
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Isoniazid therapy in Parkinson's disease</title><author><name sortKey="Gershanik, O S" sort="Gershanik, O S" uniqKey="Gershanik O" first="O. S." last="Gershanik">O. S. Gershanik</name></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name></author><author><name sortKey="Scipioni, O" sort="Scipioni, O" uniqKey="Scipioni O" first="O." last="Scipioni">O. Scipioni</name></author><author><name sortKey="Obeso" sort="Obeso" uniqKey="Obeso" last="Obeso">Obeso</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FFD9ADACCDB7B70F1965CE433BC822FCD1B072E8</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1002/mds.870030205</idno><idno type="url">https://api.istex.fr/document/FFD9ADACCDB7B70F1965CE433BC822FCD1B072E8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003199</idno><idno type="wicri:Area/Istex/Curation">003199</idno><idno type="wicri:Area/Istex/Checkpoint">004543</idno><idno type="wicri:doubleKey">0885-3185:1988:Gershanik O:isoniazid:therapy:in</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:3221901</idno><idno type="wicri:Area/PubMed/Corpus">005013</idno><idno type="wicri:Area/PubMed/Curation">005013</idno><idno type="wicri:Area/PubMed/Checkpoint">005032</idno><idno type="wicri:Area/Ncbi/Merge">004618</idno><idno type="wicri:Area/Ncbi/Curation">004618</idno><idno type="wicri:Area/Ncbi/Checkpoint">004618</idno><idno type="wicri:doubleKey">0885-3185:1988:Gershanik O:isoniazid:therapy:in</idno><idno type="wicri:Area/Main/Merge">009912</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:89-0077706</idno><idno type="wicri:Area/PascalFrancis/Corpus">003A57</idno><idno type="wicri:Area/PascalFrancis/Curation">002D68</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003A45</idno><idno type="wicri:doubleKey">0885-3185:1988:Gershanik O:isoniazid:therapy:in</idno><idno type="wicri:Area/Main/Merge">009959</idno><idno type="wicri:Area/Main/Curation">006543</idno><idno type="wicri:Area/Main/Exploration">006543</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Isoniazid therapy in Parkinson's disease</title><author><name sortKey="Gershanik, O S" sort="Gershanik, O S" uniqKey="Gershanik O" first="O. S." last="Gershanik">O. S. Gershanik</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Sección de Enfermedades Extrapiramidales, Centro Neurológico, Hospital Francés, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Movimientos Anormales, Departmento de Neurologia, Clinica Universitaria, Universidad de Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Scipioni, O" sort="Scipioni, O" uniqKey="Scipioni O" first="O." last="Scipioni">O. Scipioni</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Sección de Enfermedades Extrapiramidales, Centro Neurológico, Hospital Francés, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Obeso" sort="Obeso" uniqKey="Obeso" last="Obeso">Obeso</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Movimientos Anormales, Departmento de Neurologia, Clinica Universitaria, Universidad de Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1988">1988</date><biblScope unit="vol">3</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="133">133</biblScope><biblScope unit="page" to="139">139</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">FFD9ADACCDB7B70F1965CE433BC822FCD1B072E8</idno><idno type="DOI">10.1002/mds.870030205</idno><idno type="ArticleID">MDS870030205</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>Dyskinesia, Drug-Induced (cerebrospinal fluid)</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dyskinesias</term><term>Female</term><term>Human</term><term>Humans</term><term>Isoniazid (cerebrospinal fluid)</term><term>Isoniazid (pharmacokinetics)</term><term>Isoniazid (therapeutic use)</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Isoniazid</term></keywords><keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Isoniazid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Isoniazid</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Homme</term><term>Isoniazide</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The effect of isoniazid on levodopa‐induced dyskinesias has been evaluated in 20 patients with Parkinson's disease, following a serendipitous observation that choreic dyskinesias induced by levodopa in one parkinsonian patient were markedly reduced during treatment with isoniazid for tuberculous infection. A mean average isoniazid dose of 290 mg was given without any change in current antiparkinsonian treatment. “Benefit of dose” choreic dyskinesias were markedly reduced in 18 patients within the first few weeks of treatment. This effect was accompanied by an intolerable worsening of parkinsonian signs. All patients returned to their basal situation after isoniazid interferes with the therapeutic action of levodopa and dopamine agonists. The precise mechanism by which this action occurred is not known, but several possible explanations are discussed.</div></front></TEI><affiliations><list><country><li>Argentine</li><li>Espagne</li></country></list><tree><country name="Argentine"><noRegion><name sortKey="Gershanik, O S" sort="Gershanik, O S" uniqKey="Gershanik O" first="O. S." last="Gershanik">O. S. Gershanik</name></noRegion><name sortKey="Scipioni, O" sort="Scipioni, O" uniqKey="Scipioni O" first="O." last="Scipioni">O. Scipioni</name></country><country name="Espagne"><noRegion><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name></noRegion><name sortKey="Obeso" sort="Obeso" uniqKey="Obeso" last="Obeso">Obeso</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006543 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006543 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FFD9ADACCDB7B70F1965CE433BC822FCD1B072E8
|texte= Isoniazid therapy in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |